menu
    • menu
    [{"orgOrder":0,"company":"Zhejiang Medicine Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Nemonoxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Nephrology","graph2":"Phase I","graph3":"Zhejiang Medicine Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zhejiang Medicine Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Medicine Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Nemonoxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Undisclosed","graph2":"Phase I","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TaiGen Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TaiGen Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Nemonoxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Undisclosed","graph2":"Phase I","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TaiGen Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TaiGen Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Qualitix Clinical Research | Parexel | PPD","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Nemonoxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TaiGen Biotechnology \/ Qualitix Clinical Research | Parexel | PPD","highestDevelopmentStatusID":"10","companyTruncated":"TaiGen Biotechnology \/ Qualitix Clinical Research | Parexel | PPD"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"QPS Holdings | R&G PharmaStudies Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Nemonoxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TaiGen Biotechnology \/ QPS Holdings | R&G PharmaStudies Co","highestDevelopmentStatusID":"10","companyTruncated":"TaiGen Biotechnology \/ QPS Holdings | R&G PharmaStudies Co"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Nemonoxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TaiGen Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"TaiGen Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Nemonoxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TaiGen Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"TaiGen Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Medicine Co Ltd","sponsor":"Huashan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Nemonoxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Zhejiang Medicine Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Medicine Co Ltd \/ Huashan Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Medicine Co Ltd \/ Huashan Hospital"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Luminarie","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibiotic","year":"2020","type":"Licensing Agreement","leadProduct":"Nemonoxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TaiGen Biotechnology \/ Luminarie","highestDevelopmentStatusID":"15","companyTruncated":"TaiGen Biotechnology \/ Luminarie"},{"orgOrder":0,"company":"R-Pharm","sponsor":"OCT Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Nemonoxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"R-Pharm \/ OCT Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"R-Pharm \/ OCT Clinical Trials"}]

    Find Clinical Drug Pipeline Developments & Deals for Nemonoxacin

    Menu

    Nemonoxacin

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TaiGen Biotechnology

                            Taiwan arrow
                            Neuroscience
                            Not Confirmed

                            TaiGen Biotechnology

                            Taiwan arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oral Nemonoxacin in Treating Elderly Patients With CAP

                            Details : Nemonoxacin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Community-Acquired Pneumonia.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            November 24, 2021

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TaiGen Biotechnology

                            Taiwan arrow
                            Neuroscience
                            Not Confirmed

                            TaiGen Biotechnology

                            Taiwan arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Luminarie

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            TaiGen Out-Licensed Taigexyn® to Luminarie Canada for Canada, Australia and New Zealand

                            Details : Under the terms of the agreement, Luminarie will be responsible for the development, registration and commercialization of Taigexyn® in the territory and assume all associated costs.

                            Product Name : Taigexyn

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            September 30, 2020

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Luminarie

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            R-Pharm

                            Country arrow
                            Neuroscience
                            Not Confirmed

                            R-Pharm

                            Country arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : OCT Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia

                            Details : Nemonoxacin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pneumonia, Bacterial.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            June 11, 2018

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : OCT Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            TaiGen Biotechnology

                            Taiwan arrow
                            Neuroscience
                            Not Confirmed

                            TaiGen Biotechnology

                            Taiwan arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Evaluating the Effect of a Single-dose Oral Administration of Nemonoxacin Capsule on QTc Intervals and...

                            Details : Nemonoxacin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            December 05, 2017

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Zhejiang Medicine Co Ltd

                            China arrow
                            Neuroscience
                            Not Confirmed

                            Zhejiang Medicine Co Ltd

                            China arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Severe Impaired Renal Function

                            Details : Nemonoxacin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Kidney Diseases.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            July 21, 2016

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Zhejiang Medicine Co Ltd

                            China arrow
                            Neuroscience
                            Not Confirmed

                            Zhejiang Medicine Co Ltd

                            China arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Huashan Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function

                            Details : Nemonoxacin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Diseases.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            November 13, 2015

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Huashan Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            TaiGen Biotechnology

                            Taiwan arrow
                            Neuroscience
                            Not Confirmed

                            TaiGen Biotechnology

                            Taiwan arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP

                            Details : Nemonoxacin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Community-Acquired Pneumonia.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            July 31, 2014

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            TaiGen Biotechnology

                            Taiwan arrow
                            Neuroscience
                            Not Confirmed

                            TaiGen Biotechnology

                            Taiwan arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : QPS Holdings | R&G PharmaStudies Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Malate Sodium Chloride

                            Details : Nemonoxacin is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pneumonia.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            September 18, 2013

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : QPS Holdings | R&G PharmaStudies Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            TaiGen Biotechnology

                            Taiwan arrow
                            Neuroscience
                            Not Confirmed

                            TaiGen Biotechnology

                            Taiwan arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Qualitix Clinical Research | Parexel | PPD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Efficacy and Safety of Oral Administration With Nemonoxacin and Levofloxacin in Patients...

                            Details : Nemonoxacin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pneumonia.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            February 08, 2012

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Qualitix Clinical Research | Parexel | PPD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            TaiGen Biotechnology

                            Taiwan arrow
                            Neuroscience
                            Not Confirmed

                            TaiGen Biotechnology

                            Taiwan arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study on Oral Nemonoxacin Malate Capsules

                            Details : Nemonoxacin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            July 15, 2011

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth